The use of nuclear weapons is repeatedly discussed in the media. But what would be the effects of a nuclear strike regarding the initial radioactive radiation? Gamma radiation plays a special role here – because its effects on living beings are devastating. Due to its high penetration power and energy, gamma radiation has significant, long-lasting effects on the human body: Biological effect Gamma radiation is a high-energy form of ionizing radiation that can penetrate deep into the body[2]. When penetrating tissue, it can: Health consequences The effects depend on the radiation dose: Acute effects (at high doses) Long-term consequences Protective measures Since gamma radiation is very penetrating, thick shielding made of lead or concrete is necessary to block it effectively[3]. Strict radiation protection measures are applied in the medical and industrial fields to minimize exposure. In summary, gamma radiation is potentially very harmful to… 

Alpha radiation and radioactive fallout pose serious health risks in the event of nuclear accidents or attacks. A thorough understanding of the dangers and appropriate protective measures is crucial for disaster preparedness and personal safety. Characteristics of Alpha Radiation Alpha radiation consists of doubly positively charged helium nuclei and has the following characteristics: Protective Measures Against Alpha Radiation Radioactive Fallout Radioactive fallout refers to the deposition of radioactive particles after a nuclear explosion or reactor accident. It represents a more complex threat, as it can encompass various types of radiation. Protective Measures Against Radioactive Fallout Long-Term Measures The intensity of fallout radiation decreases over time. After 24 hours, radioactive dust has already lost 80 percent of its energy3. Nevertheless, depending on the severity of the incident, long-term protective measures such as evacuations or decontaminations may be necessary. Conclusion Effective protection against alpha radiation and radioactive fallout requires a combination of knowledge, preparation, and appropriate behavior. Following the "3 A's rule" of radiation protection… 

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics for the treatment of oncogenic and immunologic dysregulations that drive cancer, today announced that the first patient has been enrolled in its Phase 2 dose expansion study evaluating ST316, the company’s first-in-class antagonist of β-catenin. ST316 is designed to selectively turn off the Wnt/β-catenin signaling pathway in tumor cells but not in normal cells, enabling anti-cancer activity without the toxicity associated with broad inhibition of this pathway. The Wnt/β-catenin signaling pathway is one of the most active signaling pathways in various cancers and is responsible for more than 80% of colorectal cancers (CRC), the first indication being investigated in the ST316 Phase 2 expansion. More than 1 million people in the United States are living with colon cancer, and an additional 150,000 cases are expected to be diagnosed this year alone.

Myrtelle Inc. today announced the results of a clinical study showing a significant change in biomarkers in patients treated with the company’s gene therapy for Canavan disease (CD), rAAV-Oligo001-ASPA. Analysis of cerebrospinal fluid (CSF) from seven patients, observed for up to 24 months post-treatment, revealed that each patient experienced a greater than 80% decrease in N-acetylaspartate (NAA) from baseline. Observation of these patients via magnetic resonance imaging (MRI) also showed an increase in white matter and myelin volume over the same time intervals. The company’s open-label, Phase 1/2 First-in-Human (FIH) clinical study is being conducted at Dayton Children’s Hospital (Dayton, Ohio) and includes baseline and post-treatment evaluations at 1, 3, 6, and 12 months in the first year after surgery, and then every 12 months for 5 years. Myrtelle’s FIH study utilizes the company’s proprietary rAAV vector,…